Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,138 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Depressive Disorder NOS Clear all
Completed Not applicable Interventional

PRISM for Depression and Anxiety in Young Adults With Cancer

NCT06502483
View directory record Official record
Conditions
Cancer Diagnosis, Non-Metastatic Neoplasm, Anxiety, Anxiety Disorders, Depression, Depressive Disorder, Depression, Anxiety, Desmoid
Interventions
Promoting Resilience in Stress Management Program
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 39 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 5, 2026, 9:15 AM EDT
Terminated Phase 2 Interventional Results available

Org 24448 to Treat Major Depression

NCT00113022
View directory record Official record
Conditions
Depression
Interventions
Org 24448, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
21 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Phase 4 Interventional

Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS)

NCT00479726
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
duloxetine hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 27, 2007 · Synced Sep 5, 2026, 9:15 AM EDT
Not yet recruiting Phase 3 Interventional

A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

NCT07775300
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Brenipatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 5, 2026, 9:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Exposure to Stress, Postpartum Mood, Adverse Life Events, and Hormonal Function Among Latinas (SEPAH Latina)

NCT01912833
View directory record Official record
Conditions
Postpartum Depression
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 7, 2014 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)

NCT00644358
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
vilazodone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
38
States / cities
Garden Grove, California • San Diego, California • Torrance, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 5, 2026, 9:15 AM EDT
Completed No phase listed Observational

Translational Investigation of Gestational Environment on Neurobehavioral Function in Children

NCT02715778
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2020 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression

NCT06285916
View directory record Official record
Conditions
Depression, Postpartum, Postpartum Depression, Post-partum Depression, Postnatal Depression, Post-Natal Depression
Interventions
NORA520 Dose 1, NORA520 Dose 2, Placebo
Drug
Lead sponsor
TWi Biotechnology, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Bentonville, Arkansas • Anaheim, California • Canoga Park, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

NCT02614547
View directory record Official record
Conditions
Severe Postpartum Depression
Interventions
SAGE-547, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Atlanta, Georgia • Worcester, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 5, 2026, 9:15 AM EDT
Withdrawn Phase 1 Interventional

Title: Safety and Feasibility of Individualized Low Amplitude Seizure Therapy (iLAST)

NCT03895658
View directory record Official record
Conditions
Unipolar Depression
Interventions
MRI, MagPro TMS stimulator and coil, Thymatron (R) System IV paired with 4X1 HDECT
Device
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
22 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Phase 4 Interventional

The Effect of Celecoxib on Neuroinflammation in MDD

NCT04814355
View directory record Official record
Conditions
Major Depressive Disorder, Neuroinflammation
Interventions
Celecoxib 400 mg
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 5, 2026, 9:15 AM EDT
Withdrawn Not applicable Interventional

Lifestyle MIND- Feasibility of Wait-list Control

NCT06384521
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Serious Mental Illness, Schizophrenia, Major Depression, Bipolar Disorder
Interventions
Lifestyle MIND
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 5, 2026, 9:15 AM EDT
Not yet recruiting Not applicable Interventional

Mobile Cognitive Behavioral Therapy in Early Stroke Recovery

NCT07639606
View directory record Official record
Conditions
Anxiety, Stroke, Depression - Major Depressive Disorder
Interventions
Mobile Cognitive Behavioral Therapy App
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 79 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 5, 2026, 9:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glucocorticoid Effects on Cellular Cytokine Release

NCT00001415
View directory record Official record
Conditions
Depressive Disorder, Fatigue Syndrome, Chronic, Fibromyalgia, Healthy, Inflammation
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 5, 2026, 9:15 AM EDT
Withdrawn No phase listed Observational

Using EEG to Predict Depression Treatment Response to rTMS in Patients With Major Depression

NCT04575285
View directory record Official record
Conditions
Major Depression, Repetitive Transcranial Magnetic Stimulation
Interventions
Electroencephalogram (EEG)
Diagnostic Test
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Sep 5, 2026, 9:15 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans

NCT04711915
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
0.1 mg/kg Dimethyltryptamine (DMT), 0.3 mg/kg Dimethyltryptamine (DMT)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 5, 2026, 9:15 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

NICU Utilization of Remote Voice Technology to Improve mateRnal Experience (NURTURE)

NCT07214597
View directory record Official record
Conditions
Postpartum Depression (PPD), Self-Efficacy, Parental Anxiety, Engagement, Patient, Usability, Length of Stay
Interventions
VoiceLove mobile phone application
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ketamine + Mindfulness for Depression

NCT05168735
View directory record Official record
Conditions
Depression, Unipolar
Interventions
Intravenous Ketamine, Brief Mindfulness Exercises, Academic Exercises
Drug · Behavioral
Lead sponsor
Rebecca Price
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 5, 2026, 9:15 AM EDT
Recruiting Phase 3 Interventional

Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06786624
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NBI-1065845, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Little Rock, Arkansas • Garden Grove, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Not applicable Interventional

Life Improvement Following Traumatic Brain Injury

NCT00878150
View directory record Official record
Conditions
Traumatic Brain Injury, Depression
Interventions
In-person Cognitive Behavioral Therapy, Telephone Cognitive Behavioral Therapy
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 17, 2013 · Synced Sep 5, 2026, 9:15 AM EDT
Terminated Phase 3 Interventional Results available

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

NCT02871297
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
7 Years to 18 Years
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Tucson, Arizona • Wichita, Kansas • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Sep 5, 2026, 9:15 AM EDT
Recruiting Phase 4 Interventional

Aβ Dynamics in LLMD

NCT05004987
View directory record Official record
Conditions
Alzheimer Disease, Major Depressive Disorder
Interventions
Escitalopram Oxalate, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

NCT02134808
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Creatine, Placebo
Drug
Lead sponsor
Perry Renshaw
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder

NCT00511810
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Low Dose Fish Oil, High Dose Fish Oil
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Sep 5, 2026, 9:15 AM EDT